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Abstract
CVX-045 is produced by covalently attaching a thrombospondin 1 (TSP-1) mimetic comprising a peptidic sequence
and a linker to the Fab binding site of a proprietary scaffold antibody. CVX-045 possesses the potency of the TSP-1–
derived peptide, along with the advantageous pharmacokinetics of an antibody. Antitumor activity of CVX-045 was
evaluated in human xenograft models alone and in combination with standard chemotherapies and targeted mole-
cules. In A549 and A431 xenograft models, CVX-045 demonstrated significant (P < .05) antiangiogenic activity, re-
ducing tumor microvessel density and increasing the levels of necrosis within treated tumors. In an HT-29 xenograft
model, CVX-045 in combination with 5-fluorouracil significantly (P < .01) decreased tumor growth rate compared
with vehicle, CVX-045, or 5-fluorouracil alone. Cotreatment of CVX-045 plus CPT-11 delayed progression of tumor
growth from day 28 to 60. In contrast CVX-045 alone treatment did not delay the progression of tumor growth,
and CPT-11 alone delayed progression of tumor growth to day 39. Cotreatment of CVX-045 with sunitinib extended
the time to reach tumor load from day 26 to 40. In summary, CVX-045 exhibits significant antiangiogenic activity in
several tumor models and enhances antitumor activity in combination with chemotherapy or targeted therapies.
These data suggest future avenues for effective combination therapy in treating solid tumors. CVX-045 has recently
completed a phase 1 trial in solid tumors where it has been well tolerated.
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Introduction
Angiogenesis is the process whereby preexisting blood vessels can be
induced to sprout, leading to an increase in local vasculature [1]. The
process is important in a variety of physiological events such as
wound healing and the menstrual cycle in female reproductive organs
[2]. The angiogenic process is tightly regulated by both positive and
negative effectors [3]. Positive regulators of angiogenesis include vas-
cular endothelial growth factor (VEGF), fibroblast growth factors
(FGFs), epidermal growth factor, and hepatocyte growth factor.
These factors can induce endothelial cells to migrate, proliferate, or
form tube-like structures. There are also several negative regulators of
angiogenesis, such as thrombospondin 1 (TSP-1), and small “cryp-
tic” fragments of larger proteins that are intimately involved in co-
agulation and fibrinolysis [4]. Under normal conditions, angiogenesis
is activated and deactivated in a tightly coordinated sequence of
events as evidenced, for example, in wound healing [5].
Tumors have been described as “wounds that never heal” [6], in
that they upregulate or induce the up-regulation of positive effectors
of angiogenesis, but do not balance this process with the expression
of negative regulators. In essence, tumors have turned on the angio-
genic switch and cannot turn it off, and it has been suggested that the
endothelial compartment of a tumor would be a good target for ther-
apeutic intervention [7]. To date, most efforts have attempted to at-
tenuate the effects of the positive regulators through growth factor
traps such as Avastin [8] or growth factor receptor antagonists such
as Sutent [9]. However, amplifying the effects of known negative
regulators of angiogenesis such as TSP-1 also has potential for anti-
angiogenic intervention.
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TSP-1 is a 420-kDa matrix protein that not only inhibits adhe-
sion, proliferation, and tube formation by several types of endothelial
cells but also inhibits angiogenesis in the chorioallantoic membrane
assay [10]. TSP-1 has also been used to successfully treat cancer in a
mouse model [11]. However, the use of TSP-1 as an antiangiogenic
drug in humans is prohibitive owing to both its size and multiple
other biologic activities.
TSP-1 is a trimer, with each promoter composed of multiple do-
mains including three types of sequence motifs (type 1, 2, and 3 re-
peats [12]). TSP-1 has three type 1 repeat (TSR) domains. Within
the TSR domains, the sequence GVITRIR seems to demonstrate
antiangiogenic activity with the adjacent sequence CSVTCG, pro-
viding some form of enhancement of activity [13]. Peptides based
on the GVITRIR sequence of TSR have been reported to inhibit
the migration of endothelial cells and have been used successfully
to treat metastatic tumors in syngeneic mouse models as well as
orthotopic bladder tumors in immune-deficient mice [14]. However,
both tumor models required twice-daily administration of the TSP-1–
derived peptide.
It is all too common for bioactive compounds with excellent anti-
cancer efficacy in vitro to fail in the clinic because of a requirement
for therapy-intensive treatment regimens. We show here that a TSP-1
mimetic pharmacophore with potent antiangiogenic activity can be
combined with a proprietary reactive monoclonal antibody to create
a CovX-Body termed CVX-045. We describe here the efficacy of
CVX-045 administered as a monotherapy in tumor xenografts and
in combination with chemotherapy or targeted therapy such as that
including irinotecan, 5-fluorouracil (5-FU), and Sutent. CVX-045 sig-
nificantly reduces microvessel density, induces apoptosis, and increases
the necrotic core of treated tumors. CVX-045 has recently completed
a phase 1 trial [15]. The data provided here suggest possible com-




Sunitinib was obtained from Biomol International (Plymouth Meet-
ing, PA), and CPT-11 and 5-FU were obtained from Henry Schein
(Melville, NY).
Production of CVX-045
The synthesized pharmacophore (azetidinone-PEG-Pro-Gly-Val-
(D-alloIle)-Thr-Nva-Ile-Arg-Pro-NHEt) was programmed at a 4:1 ra-
tio (pharmacophore/Ab) at 25°C for 24 hours. After programming,
free pharmacophore was removed using gel filtration (PD-10 column;
17-0851-01; Amersham, Piscataway, NJ). The final protein concentra-
tion was determined by monitoring the absorbance at 280 nm, and
programming efficiency was confirmed by mass spectrometry analysis
of the column-purified dosing solution. Dosing solution was diluted to
working concentrations with phosphate-buffered saline (PBS). All dos-
ing solutions were prepared fresh 1 or 2 days before dosing and stored
at 4°C until use.
Endothelial Cell Migration
Endothelial cell migration was performed as described [16]. Hu-
man dermal microvascular endothelial cells (Cambrex, Walkersville,
MD) and bovine adrenal microvascular endothelial cells (VEC Tech-
nologies, Rensselaer, NY) were grown in VEC endothelial cell com-
plete medium. Confluent (80%-90%) endothelial cells were starved
overnight in endothelial basal medium (EBM)/bovine serum albumin
(BSA; Cambrex, Walkersville, MD) containing 0.1% BSA (Sigma, St
Louis, MO). Cells were then harvested with trypsin/EDTA (0.05%;
Mediatech, Herndon, VA) and resuspended in EBM/BSA at a concen-
tration of 1.5 to 2.0 × 106 cells/ml. Cells (29 μl) were added to the
bottom of a modified Boyden chamber (Nucleopore, Gaithersburg,
MD) and covered with gelatinized PVDF Nucleopore membrane
(Whatman, Florham Park, NJ), placed with the milky side facing
the cells and shiny side away from the cells. The chambers were assem-
bled and inverted, and the cells were allowed to adhere for 90 minutes
at 37°C. Recombinant human basic fibroblast growth factor (bFGF;
20 ng/ml; R&D Systems, Minneapolis, MN) or 0.25% to 0.5% fetal
bovine serum (FBS; Tissue Culture Biologicals, Tulare, CA) were used
for a positive control as indicated, and EBM/BSA was used for a neg-
ative control. EBM/BSA, inducers (20 ng/ml bFGF or 0.25% FBS,
prepared in EBM/BSA), and TSP-1 (Calbiochem, San Diego, CA)
(20 nM) + inducer were also included in each chamber to monitor
the success of the assay. Background migration was subtracted, and
the data presented as a percentage of bFGF or FBS-induced migration
(% maximal migration) ± SEM.
General Animal Methods
Young adult female Nu-Foxn1nu mice (Charles River Laboratories,
Wilmington, MA) were housed 5 to 10 per cage in a temperature-
and light-controlled vivarium (lights on-off 12:12 hours) with standard
laboratory chow and water available ad libitum. All husbandry materials
were sterilized by autoclaving.Mice were allowed to rest undisturbed for
at least 48 hours after arrival before experimentation was initiated. All
animal experiments were conducted after protocol approval by the
CovX Institutional Animal Care and Use Committee.
Matrigel Plug Assay
Growth factor–reduced Matrigel (catalog no. 354230; BD Biosci-
ences, San Diego, CA) was brought to the liquid phase by placing on
ice for several hours. Recombinant human bFGF (catalog no. 356060;
BD Biosciences) was added to the Matrigel to a final concentration of
100 ng/ml. The Matrigel was loaded into prechilled syringes that were
held on ice to maintain the material in the liquid state for injection.
Mice (Nu-Foxn1nu) were anesthetized by isoflurane inhalation
for subcutaneous injection of the Matrigel (0.5 ml/mouse) in the
upper abdominal region. In initial studies, treatment was initiated 3
to 4 hours later on the same day. Five mice were randomly assigned
to each treatment group, and treatment (0.1-1 mg/kg administered
intravenously in 0.2 ml of PBS) was given once on day 0 and Matrigel
plugs and were allowed to mature for 7 days. At the end of the 7-day
period, mice were killed by CO2 asphyxiation and Matrigel implants
(“plugs”) were carefully dissected free of surrounding tissue.
Quantification of Angiogenesis in the Matrigel Plug
Implants were snap frozen on liquid nitrogen and embedded inOCT,
and frozen 5-μm sections were prepared on a cryostat. Three- to five-
step sections (5 μm every 30 μm) were mounted on slides and fixed
by routine histologic procedures. CD31 immunoreactivity was local-
ized using a rat antimouse CD31 antibody (catalog no. 550274; BD
Pharmingen, San Diego, CA) and detected using an antirat IgG–
horseradish peroxidase (HRP) detection kit (catalog no. 551013; BD
Pharmingen). Slides were then photographed andCD31-immunopositive
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staining of the imageswas quantified using ImagePro 5.1 software. Total
CD31 immunoreactivity was summed over all five sections for each
Matrigel implant and expressed as pixels per plug. All analyses were
conducted by operators blinded to the treatment groups.
Pharmacokinetics Studies
The pharmacokinetics (PK) of CVX-045, were determined in
male Swiss Webster mice (Charles River Laboratories). Mice were
dosed with CovX-Bodies at 10 mg/kg intravenously; blood samples
from three mice per time point were taken at 0.08, 0.25, 0.5, 1, 2, 4,
6, and 24 hours; and serum samples were prepared by centrifugation.
CVX-045 concentrations were determined using a rabbit polyclonal
antibody generated against the TSP-1 peptidomimetic portion of
CVX-045 in a capture ELISA. In brief, plates were coated with anti-
peptidomimetic antibody, and serum samples added. The Fc portion
of CVX-045 was then detected by the addition of HRP-conjugated
donkey antihuman IgG (Bethyl Laboratories, Montgomery, TX) and
TMB developing solution (Kirkegaard and Perry Laboratories,
Gaithersburg, MD).
Xenograft Tumor Studies
Tumor cell lines were cultured in RPMI 1640 medium with 10%
FBS in a 5% CO2 incubator with 98% humidity. Subconfluent cells
(70%-80%) were harvested after brief treatment with 0.25% trypsin
and resuspended in Hank’s balanced salt solution for inoculation.
Tumor cell suspensions (3-5 × 106 cells, depending on the cell line)
were injected SC in a volume of 0.2 ml into the right flank of each
mouse. In studies where drug was administered concurrently with tu-
mor inoculation, 8 to 10 mice were randomly assigned to each treat-
ment group, and treatments were conducted for up to 4 weeks. In all
other studies, treatments were initiated the day after tumor inoculation
and continued for up to 4 weeks. Tumor measurements were made
periodically with manual calipers at least weekly, and tumor volumes
were calculated using the formula: 0.52 × length × width2. At the end
of the study, tumors were excised and weighed, and then for some
studies, tumors were analyzed (immuno)histochemically. In studies
where tumors were staged, tumor measurements were made with
manual calipers at least weekly, and once the required average tumor
volume was attained, animals were randomized into groups of 8 to
10, and treatment was initiated within 24 hours. For pseudomortal-
ity study designs, each group was killed as the tumor mean volume
reached either 1000 or 2000 mm3.
Quantification of Viable Tumor Area
A ∼3-mm section through the midportion of each tumor was
fixed in formalin and paraffin embedded. Five-micrometer sections
were prepared on a microtome and mounted on slides. Sections were
stained with H&E following standard histologic procedures and then
photographed using a QImaging MicroPublisher 5.0 RTV camera
(Burnaby, British Columbia, Canada) coupled with a Nikon Eclipse
80i microscope (2×; Nikon, Melville, NY). An adjacent cross section
of ∼3 mm was frozen on liquid nitrogen and then embedded in
OCT for preparation of frozen sections using a cryostat.
To determine necrotic and viable tumor area, whole field images
of each stained tumor section were acquired at low magnification.
ImagePro 5.1 software or ImageJ software (National Institutes of
Health, Bethesda, MD) was used to quantify the necrotic and viable
area by using the tracing function of measurement. For each tumor
tissue, two to five measurements were collected and exported to a
Microsoft Excel file (Microsoft Corp, Redmond, WA). The percent-
age of viable tissue area was calculated as the following formula: vi-
able area (%) = [total tissue area − necrotic area] / total tissue area. All
photography and image analysis was conducted by operators blinded
to the treatment groups.
Quantification of Microvessel Density
Snap-frozen tumor sections were oriented and embedded in OCT
blocks. Three 5-μm sections (one section every 150 μm) were obtained
from each block using a Leica CM1850 Cryostat, Buffalo Grove, IL.
The slides were immediately fixed in cold acetone for 2 minutes and
air-dried. CD31 immunohistochemical staining of blood vessels was car-
ried out using an antirat IgG-HRP detection kit (catalog no. 551013;
BD Pharmingen) and followed the methods in the kit’s instruction
manual. The CD31 antibody (catalog no. 550274; BD Pharmingen)
was diluted 1:200. The CD31-positive area in each tumor was imaged
using a Qimaging Micropublisher 5.0 RTV camera coupled with a
Nikon Eclipse 80i microscope (20×). Five evenly spaced images were
taken along a cross section of each tumor starting and ending at a point
on the viable rim in which CD31 staining was greatest. ImagePro 5.1
software was used to quantify the CD31-positive area using a common
quantitative macro throughout the experiment. CD31-positive pixels/
per 20× microscopic field was calculated by dividing the total CD31-
positive area of the three sections of each tumor by 15 (five fields from
each of three sections from each tumor). All analyses were conducted
by operators blinded to the treatment groups.
Quantification of Apoptosis
Tumor frozen sections (5 μm thickness) were processed for double
immunofluorescence staining of cleaved caspase 3 and CD31. Slides
were treated with an autofluorescence eliminator reagent (catalog no.
2160; Chemicon, Temecula, CA) for 2 minutes and then treated
with streptavidin-biotin block (catalog no. SP-2002; Vector Laborato-
ries, Burlingame, CA) for 30 minutes and nonspecific staining block
with 2.5% BSA for 15 minutes. Sections were incubated overnight at
4°C with a cocktail of primary antibodies against cleaved caspase 3
(catalog no. 9664 rabbit mAb, diluted 1:100; Cell Signaling Technol-
ogy, Danvers, MA) and mouse CD31 (rat antimouse CD31, catalog
no. 550274, diluted 1:50; BD Pharmingen). The second antibody
for cleaved caspase 3 was biotinylated goat-antirabbit IgG (catalog
no. PK-6101, diluted 1:200; Vector Laboratories), which was incu-
bated at room temperature for 1 hour. The slides were then treated
with a cocktail of Alexa Fluor 555–conjugated strepavidin (catalog
no. S32355, diluted 1:400; Invitrogen, Carlsbad, CA) for the de-
tection of cleaved caspase 3 and -labeled polyclonal antirat IgG (cat-
alog no. 554016, diluted 1:100; BD Pharmingen) for CD31, both of
which were incubated at room temperature for 1 hour. Sections were
rinsed with PBS between each step. After staining the slides were
mounted with Antifade with 4′,6-diamidino-2-phenylindole (DAPI)
kit (catalog no. 24636; Invitrogen).
Fluorescence images of cleaved caspase 3, CD31, and nuclei were
collected using a Nikon fluorescence microscope equipped with ap-
propriate filters and merged using ImagePro 5.1 software. For quan-
tification of apoptosis, three images at 20× microscopic field from
each tumor section at the viable rim (area with the most apoptotic
cells) were collected and summed. Cleaved caspase 3 immunofluores-
cence is expressed as pixels per 20× field. All analyses were conducted
by operators blinded to the treatment groups.
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Quantification of Proliferation
Immmunofluorescence staining of PCNA was carried out on one
frozen section (5 μm thickness) of each tumor. Frozen section slides
were stained with rabbit anti-PCNA polyclonal antibody (catalog no.
ab2426, diluted 1:100; Abcam, Cambridge, MA) overnight at 4°C
after treatment with autofluorescence eliminator reagent (catalog
no. 2160; Chemicon) for 5 minutes. The second antibody for PCNA
used was Alexa Fluor 488–conjugated goat antirabbit IgG (catalog
no. A11034, 1:300; Invitrogen) and incubated at room temperature
for 1 hour. Sections were rinsed with PBS containing 0.05% Tween
20 between each step. After staining, the slides were mounted with
ProLong Gold Antifade reagent with DAPI (catalog no. P36935;
Invitrogen) for nuclear staining. Three fluorescence images of PCNA
and nuclei from each section were collected using a Qimage Retiga
2000R camera coupled with a Nikon Eclipse 80i fluorescence micro-
scope equippedwith tetramethyl rhodamine isothiocyanate/rhodamine,
fluorescein isothiocyanate, and DAPI filter cubes, respectively, at each
40× microscopic field. The collected images were then processed,
merged, and analyzed using ImagePro 6.1 software. Quantification
of proliferation was calculated as percentage of PCNA-positive nuclei
over total DAPI nuclei per 40× field.
Statistical Analyses
Datawere analyzed either by one-way analysis of variance (ANOVA) fol-
lowed byDunnett post hoc analysis or two-wayANOVAwith aBonferroni
post test using Prism Ver 4.0 (GraphPad Software, San Diego, CA).
Results
CVX-045 Inhibits Angiogenesis In Vitro and In Vivo
In Boyden chamber experiments, CVX-045 inhibited the FBS-
induced migration of endothelial cells with a half-maximal inhibitory
concentration (IC50) value of 1 to 10 nM (Figure 1A). The antiangio-
genic activity of CVX-045 was further evaluated in a Matrigel plug
assay. CVX-045 significantly attenuated the angiogenic response to
FGF-2 by ∼31% to 36% at a dose of 1 mg/kg or less (Figure 1B).
These data demonstrate that CVX-045 had antiangiogenic activity.
CVX-045 Reduces Viable Tumor Volume and Microvessel
Density in Tumor Xenografts
The β half-life of CVX-045 in mice was approximately 50 hours
(Table 1), suggesting that weekly dosing would be an effective sched-
ule for treating xenografts. Weekly administration of CVX-045 at a
dose of 10 mg/kg resulted in significant (P < .05, n = 9 per group)
reductions in tumor growth rate of A431 epidermoid carcinoma xeno-
grafts and A549 lung adenocarcinoma xenografts (Figure 2, A and
B). Histologic analysis of excised treated tumors demonstrated a sig-
nificant reduction in viable tumor area in both A431 and A549
xenografts compared with untreated tumors (Figure 2, C and D).
Furthermore, CVX-045 treatment caused a significant reduction
(P < .05, n = 9 per group) in microvessel density in both A431 and
A549 xenografts (Figure 2, E and F).
CVX-045 Induced Apoptosis in Tumors within
1 Hour of Administration
A549-bearing animals were treatedwithCVX-045weekly at 30mg/kg.
Tumors were excised at various time points after drug administration
and analyzed histologically for cleaved caspase 3 (apoptosis), CD31
(mvd), and PCNA (proliferation).
CVX-045–treated tumors demonstrated visible apoptosis within
1 hour of drug administration when compared with PBS-treated tu-
mors (Figure 3, A and B). Inspection of the histology images suggests
that the initial apoptosis is seen within the endothelial cell com-
partment as demonstrated by the colocalization of cleaved caspase 3
and CD31 staining (Figure 3, A–D). From weeks 2 to 4, there is a col-
lapse of the tumor cell compartment as indicated by the increase in
cleaved caspase 3 staining, evident within the tumor cell compartment
as opposed to the endothelial cell compartment (Figure 3, E–H ).
Quantification of the cleaved caspase 3 signal indicated that the in-
creased level of apoptosis attained statistical significance at weeks 2
and 4 (Figure 4A). Quantification of the CD31 staining in these tu-
mors demonstrated a decrease in microvessel density within 1 hour
Figure 1. (A) CVX-045 (–▪–) inhibits the serum-induced migration
of endothelial cells. CVX-045 (–▴–) in the absence of FBS had no
effect on endothelial cell migration. Values are mean ± SEM, n =
4. (B) CVX-045 significantly (P < .05, ANOVA, Dunnett post test,
n = 3 per group) inhibits FGF-2–induced angiogenesis at doses
of 0.1 to 1 mg/kg as determined by quantifying CD31 staining in
a Matrigel plug assay.
Table 1. Pharmacokinetic Parameters of CVX-045 in Mice.
Species AUC (h/μg per milliliter) α t12 (h) β t12 (h) Cmax (μg/ml)
Mouse 1177 (8.12) 1.60 (19.7) 53.05 (7.15) 119.4 (16.7)
Pharmacokinetic parameters of CVX-045 were derived from a two-compartment model (weighted
1/y2) calculated with theWinNonlin software after a single intravenous dose of CVX-045 (10 mg/kg)
in male Swiss Webster mice. Sampling time points range from 5 minutes to 14 days. Data are ex-
pressed as the mean (%CV).
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of drug administration, attaining statistical significance by 2 weeks
(Figure 4B). The level of proliferating cells, as quantified by PCNA
staining, also showed a statistically significant reduction by week 4
(Figure 4C ).
The effects of bevacizumab, dosed at 5 mg/kg twice weekly, to
alter various tumor parameters such as apoptosis and mvd, were also
assessed in the A549 model. These data are presented in Table 2.
CVX-045 Improves the Efficacy of Chemotherapy and
Targeted Therapy
The efficacy of CVX-045 in combination with chemotherapy and
targeted therapy was tested using either standard tumor xenograft
growth rate experiments or “pseudomortality” experimental design,
in which treatment groups were allowed to attain a predetermined
tumor volume and the time to attain that volume was recorded.
When tested in a standard growth rate experiment, neither CVX-
045 at a dose of 30 mg/kg weekly nor 5-FU at a dose of 100 mg/kg
weekly significantly affected the growth rate of HT-29 colorectal car-
cinoma xenografts (Figure 5A). However, the combination of these
drugs did result in a significant reduction in tumor growth rate (P <
.01) compared with vehicle alone (Figure 5A).
When tested in a pseudomortality experiment, CPT-11 at 100mg/kg
weekly had efficacy against HT-29 xenografts, increasing the time to
attain 2000mm3 from 27 to 39 days. This efficacy was greatly improved
Figure 2. (A) CVX-045 (–▴–) inhibits growth of A431 xenograft at a dose of 10 mg/kg administered weekly. The reduction in tumor
volume was statistically significant (P < .05, two-way ANOVA with Bonferroni correction, n = 9 per group) by day 21 when compared
with the growth of vehicle-treated tumors (–▪–). (B) CVX-045 (–▴–) inhibits growth of A549 xenograft at a dose of 10 mg/kg administered
weekly. The reduction in tumor volume was statistically significant (P < .05, two-way ANOVA with Bonferroni correction, n = 9 per
group) at day 49 when compared with the growth of vehicle-treated tumors (–▪–). (C) CVX-045 treatment (10 mg/kg 1×/wk) significantly
reduces (P < .05, one-way ANOVA, Newman-Keuls multiple comparison test, n = 5 per group) the viable tumor volume of A549 tumors
when compared with PBS-treated tumors. (D) CVX-045 treatment (10 mg/kg 1×/wk) significantly reduces (P < .05, one-way ANOVA,
Newman-Keuls multiple comparison test, n = 5 per group) the viable tumor volume of A431 tumors when compared with PBS-treated
tumors. (E) CVX-045 treatment (10 mg/kg 1×/wk) significantly reduces (P < .05, one-way ANOVA, Newman-Keuls multiple compari-
son test, n = 5 per group) the microvessel density of A549 tumors when compared with PBS-treated tumors. (F) CVX-045 treatment
(10 mg/kg 1×/wk) significantly reduces (P < .05, one-way ANOVA, Newman-Keuls multiple comparison test, n = 5 per group) the mi-
crovessel density of A431 tumors when compared with PBS-treated tumors.
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when coadministered with CVX-045 (Figure 5B), the combination did
not attain a tumor volume of 2000 mm3 until day 56 of therapy
(Figure 5B).
Combination of CVX-045 and sunitinib were also tested in ani-
mal models using HT-29 xenografts. Both CVX-045 at 30 mg/kg
weekly and sunitinib at 15 mg/kg daily were ineffective in reducing
tumor growth rate (Figure 5C ), whereas the combination of CVX-
045 and sunitinib significantly (P = .0006) reduced tumor rate com-
pared with vehicle (Figure 5C ). Tumors in animals receiving this
combination took 40 days to reach a volume of 1000 mm3 compared
with 26 days for PBS-treated controls.
Discussion
A TSP-1 mimetic CovX-body (CVX-045) was produced by covalently
linking a TSP-1 mimetic pharmacophore to a proprietary antibody.
The TSP-1 mimetic pharmacophore contains a reactive group that is
specifically recognized by the antibody Fab active site reactive lysine
and forms an irreversible covalent bond to create CVX-045. Chemically
Figure 3. (A–H) A549 tumors, treated with either PBS or CVX-045 (30 mg/kg 1×/wk), were excised at the time points indicated and
sections stained for CD31 (red) to indicate endothelial cells or cleaved caspase 3 (green) to indicate apoptotic cells. Tumor cells were
stained with DAPI (blue). Separate images were merged to give yellow regions where red and green overlay, indicating apoptotic en-
dothelial cells.
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conjugating peptides to the scaffold antibody has been demonstrated to
enhance the potency of the peptide (possibly due to bivalency) and to
enhance the PK of the pharmacophore peptide [17,18]. Thus, generat-
ing a CovX-body from a peptide allows the peptide to be administered
on an antibody-like schedule.
CVX-045 is a potent inhibitor of endothelial cell migration, as
measured in a Boyden chamber. CVX-045 is also a potent antiangio-
genic as measured in the Matrigel plug assay inhibiting angiogenesis
at doses as low as 0.1 mg/kg 1×/wk.
Other laboratories have shown that pharmacophores derived from
TSP-1 domains retained antiangiogenic function and could inhibit
tumor growth in a variety of animal models, although these small-
molecular weight pharmacophores must be administered frequently
and at high doses. CVX-045 has the PK profile of an antibody, dem-
onstrating a β t1/2 of 50 hours in mice and approximately 80 hours
in nonhuman primates. The antiangiogenic potency and PK profile
indicated that CVX-045 should have efficacy in preclinical tumor
models when dosed weekly.
CVX-045 was able to significantly reduce the growth rate of both
the squamous cell carcinoma A431 and the lung adenocarcinoma
A549 when administered intravenously at 10 mg/kg weekly. Histo-
logic analysis of excised tumors showed that CVX-045 caused a sig-
nificant reduction in both viable tumor volume and microvessel
density by the end of the study.
It is well established that decreased microvessel density, although
indicative of an antiangiogenic effect is not sufficient for complete
tumor volume reduction in hypoxia-resistant tumor models. More-
over, microvessel density is not a measure of the angiogenic depen-
dence of a tumor but, to a large degree, reflects the metabolic burden
of the supported tumor cells. A minimum vessel density is determined
by tumor cell metabolic demand, but vessel density can exceed the
metabolic requirements of a tumor. Thus, a therapy regimen that re-
duces microvessel density may not have a complete impact on tumor
volume but may have a partial impact on viable tumor area.
There is an observed decrease in viable tumor volume in A431 and
A549 tumor xenografts in response to CVX-045 therapy. This is sim-
ilar to the observation from other laboratories that have shown that
overexpression of TSP-1 in genetically engineered tumor cell lines is
also characterized by an increase in tumor necrosis in A431 and other
xenograft models [19]. These observations fit with the mechanism of
TSP-1 as an antiangiogenic molecule. If TSP-1 is causing a decrease in
angiogenesis within the tumor, this would manifest as necrotic areas,
resulting from nutrient and oxygen deprivation.
A further study of the efficacy of CVX-045 in the A549 xenograft
model revealed that CVX-045 has an observable apoptotic effect on
tumor vasculature within 1 hour of administration, and this increase
in apoptosis was statistically significant at 2 weeks. Examination of
the stained tumor sections reveals that by week 1 of therapy, the ap-
optosis is apparently confined to the tumor vasculature, whereas by
week 4, the increased apoptosis is seen in nonendothelial cells within
the tumor. This indicates that CVX-045 is having an immediate
effect on the vascular compartment of the tumor resulting in acute
Figure 4. (A) Levels of apoptotic cells (as indicated by cleaved cas-
pase 3 staining) were quantified in A549 tumor sections obtained
from tumors excised at various time points after treatment with
CVX-045 (30mg/kg 1×/wk). Therewas a significant (P< .01, ANOVA,
Tukey multiple comparison posttest, n = 5 per group) increase in
apoptosis of CVX-045–treated tumors compared with PBS-treated
tumors at 2 and 4 weeks. (B) Microvessel density (as indicated by
CD31 reactivity) was quantified in A549 tumor sections obtained
from tumors excised at various time points after treatment with
CVX-045 (30mg/kg 1×/wk). Therewas a significant (P< .05, ANOVA,
Tukey multiple comparison posttest, n = 5 per group) decrease in
microvessel density observable between PBS-treated and CVX-
045–treated tumors at 2weeks. (C) The percentage of PCNA-positive
cells was quantified in A549 tumors after 4 weeks of CVX-045 treat-
ment (30 mg/kg 1×/wk). A significant (P < .05, Mann-Whitney test,
n = 5 per group) decrease in PCNA staining was observed in the
CVX-045–treated group at 4 weeks.
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collapse of the vasculature. More its chronic effects are the subse-
quent apoptosis of tumor cells that are being deprived of oxygen and
nutrients. This does indicate that in vivo, CVX-045 is eliciting its anti-
tumorigenic effects via an antiangiogenic mechanism. Previously, we
have demonstrated that a less mature iteration of a thrombospondin
mimetic CovX-Body (CVX-22) was selectively active against pro-
liferating endothelial cells within a tumor [20]. Specifically, CVX-22
reduced the numbers of activated VEGF receptor 2–positive tumor
endothelial cells, a subset of endothelial cells that contain most of the
mitotically active endothelial cells.
Assessment of PCNA staining at week 4 of therapy revealed a sig-
nificant reduction in proliferation within the tumor, providing fur-
ther evidence that CVX-045 antitumor effects are not acute.
CVX-045, in common with most antiangiogenic agents, was able to
reduce microvessel density and decrease the viable tumor volume of
xenografts in single agent studies. However, it is well appreciated that
tumors can be partially resistant to antiangiogenic therapy owing to
the induction of gene expression as a consequence of hypoxia. All anti-
angiogenic agents thus far approved for clinical use are given in com-
bination with either chemotherapy or stand-of-care targeted therapies.
Our experience with HT-29 colorectal adenocarcinoma suggested that
this cell line was essentially resistant to CVX-045 monotherapy. We
decided to test CVX-045 in combination with 5-FU, CPT-11, and
sunitinib in this model to test whether a combination of modalities
could be effective in inhibiting tumor growth rate.
We tested these combinations in either classic growth rate models
or pseudomortality models, where the time taken by a treatment group
to reach a predetermined tumor volume is recorded and compared
with vehicle-treated groups. Although the growth rate of HT-29 xeno-
grafts was unaffected by CVX-045, 5-FU, or sunitinib monotherapy,
the combination of CVX-045 and 5-FU produced a significant reduc-
tion in tumor volume by day 30 of treatment. The combination of
CVX-045 and sunitinib was also more effective than either monother-
apy alone. CPT-11 therapy was effective in inhibiting the growth rate
of HT-29 xenografts, but the combination of CVX-045 and CPT-11
was even more effective. These data suggest that CVX-045 combines
well with other modalities, including antimetabolites, topoisomerase II
inhibitors, and tyrosine kinase inhibitors.
Table 2. Comparison of the Effects of CVX-045 and Bevacizumab on Measurable End Points in
the A549 Model.
Treatment End Points 1 wk 2 wk 4 wk
PBS
CVX-045 (30 mg/kg 1×/wk) Apoptosis * †
MVD †
Bevacizumab (5 mg/kg 2×/wk) Apoptosis * †
MVD † †
Apoptosis and MVD were measured as described. Statistical differences were determined using
ANOVA with a Bonferroni post test to compare test samples to time-matched PBS-treated controls.
MVD indicates microvessel density.
*P < .05.
†P < .001.
Figure 5. (A) Neither CVX-045 (–□–) administered at 30 mg/kg 1×/
wk nor 5-FU (–▴–) administered at 100 mg/kg intraperitoneally 1×/
wk significantly inhibit the growth of HT-29 xenograft when com-
pared with the growth rate of PBS treated tumors (–▪–). A com-
bination of these two drugs (–▾–) does inhibit the growth rate of
HT-29 tumors by day 29. The reduction in tumor volume was sta-
tistically significant (P < .05, one-way ANOVA, n = 9 per group) by
day 29 when compared with the growth of vehicle-treated tumors
(–▪–). (B) CVX-045 (–□–) administered at 30 mg/kg 1×/wk did not
significantly inhibit the growth of HT-29 xenograft when compared
with the growth rate of PBS-treated tumors (–▪–). CPT-11, adminis-
tered at 100 mg/kg 1×/wk intraperitoneally, was able to significantly
(P < .001, two-way ANOVA, n = 9 per group) inhibit the growth
of these tumors (–▴–). A combination of these two drugs (–▾–) fur-
ther significantly (P < .001, two-way ANOVA, n = 9 per group) in-
hibited the growth rate of HT-29 tumors. (C) Neither CVX-045 (–□–)
administered at 30 mg/kg 1×/wk or sunitinib (–▴–) administered at
15 mg/kg per os daily significantly inhibit the growth of HT-29 xeno-
graft when compared with the growth rate of PBS-treated tumors
(–▪–). A combination of these two drugs (–▾–) does significantly
(P< .001, two-way ANOVA, n= 9 per group) inhibit the growth rate
of HT-29 tumors.
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CVX-045 has recently completed a phase 1 clinical trial [16].
Eighteen patients with advanced solid tumors and no known bleed-
ing risk received CVX-045 administered in three-patient cohorts
(0.3, 1, 3, 6, 12, and 18 mg/kg) by once-weekly intravenous infu-
sions. Common adverse events (grade 1-2) included gastrointestinal
anemia, headache, fatigue, and general muscle weakness. Dynamic con-
trast enhanced-magnetic resonance imaging showed effects on flow
(21%–42% decrease in K trans) but not permeability (AUCBN(90))
in two of three patients in the 12-mg/kg group and in one patient in
the 6-mg/kg group. There was an unconfirmed partial response in
1 patient with liver metastases and stable disease in 5 of 12 patients.
Of 18 patients, 1 (6%) was potentially positive for an immune re-
sponse to study drug on cycle 1, day 1. All subsequent test results were
negative. All other patients with test results reported were negative. It
was concluded that CVX-045 was a well-tolerated new therapy tar-
geting angiogenesis by a novel pathway with preliminary evidence by
dynamic contrast enhanced-magnetic resonance imaging and RECIST
to suggest biologic activity in the clinic.
It is well appreciated that novel efficacious antiangiogenic therapies
will find a place in the clinic in combination with standard-of-care
therapies. CVX-045 is an antiangiogenic molecule. Antiangiogenic
effects are a phenomenon that can be driven by different molecular
mechanisms. Therapies can either inhibit angiogenesis or promote
antiangiogenesis by altering the angiogenic switch. Bevacizumab obvi-
ously traps VEGF and, in doing so, inhibits angiogenesis, whereas
CVX-045 is hypothesized to promote antiangiogenesis. Within the
modalities that inhibit VEGF-driven angiogenesis are drugs that block
signaling from inside the cell, such as sunitinib. Each of these mecha-
nisms may offer advantages and disadvantages when used in combina-
tion therapy regimens. It is known, for example, that adding sunitinib
to bevacizumab can result in increased toxicities with no discernable
benefit [21,22]. When combining antiangiogenic therapies with other
modalities, it may be that the underlying mechanism driving the anti-
angiogenic effects is the arbiter of a safe and effective combination.
Drugs such as CVX-045 may offer a combination option not available
to bevacizumab owing to underlying differences in the molecular
mechanism. The preclinical data presented here suggest possible effec-
tive combinations for CVX-045 in the future.
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